articleTop 10% cited

Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients

World Journal of Surgery · 2009 · Vol. 34(2) · pp. 249–255

Pierre Goudet✉(Université de Bourgogne)Arnaud Murat(Centre Hospitalier Universitaire de Nantes)Christine Binquet(Inserm)C. Cardot‐Bauters(Centre Hospitalier Universitaire de Lille)Annie Costa(Centre Hospitalier Universitaire Dijon Bourgogne)Philippe Ruszniewski(Hôpital Beaujon)Patricia Niccoli(Hôpital de la Timone)Fabrice MènégauxG Chabrier(Hôpital d'Hautepierre)Françoise Borson‐Chazot(Hôpital Pierre Wertheimer)Antoine Tabarin(Hôpital Cardiologique du Haut-Lévêque)Philippe Bouchard(Hôpital Saint-Antoine)Brigitte Delemer(Université de Reims Champagne-Ardenne)Albert Beckers(Centre Hospitalier Universitaire de Liège)Claire Bonithon‐Kopp(Centre Hospitalier Universitaire Dijon Bourgogne)

View via DOI Publisher page

Abstract

The prognosis of MEN1 disease has improved since 1980. Thymic tumors and duodenopancreatic tumors, including nonsecreting pancreatic tumors, increased the risk of death. Rare but aggressive adrenal tumors may also cause death. Most deaths were related to MEN1. New recommendations on abdominal and thoracic imaging are required.

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Neuroblastoma Research and TreatmentsMEN1MedicineMultiple endocrine neoplasiaGastrinomaHazard ratioInternal medicineCohortNeuroendocrine tumorsDiseaseCause of death

MeSH terms

AdultBelgiumCause of DeathDiagnostic ImagingFemaleFollow-Up StudiesFranceHumansMaleMiddle AgedPrognosisRisk FactorsChi-Square DistributionProportional Hazards ModelsSurvival Analysis

Citations

338

FWCI

7.60

field-weighted impact

References

Percentile

98%

vs. same field & year

Citations per year

Cited by

Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)